Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Chief People Officer | July 25, 2023 | July 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date July 25, 2023 · Filed July 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,761 |
Ending reported balance
After 2023-07-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-25 · Exercise / conversion · Acquired 137 · Balance 4,822 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2023-07-26 · Sale · Disposed 61 · Balance 4,761 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,091 |
Reported balance
After 2023-07-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-25 · Exercise / conversion · Disposed 137 · Balance 1,091 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2023 Filed Jul 27, 2023 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 61 | $7.41 | $452.01 |
DisclosureSEC source: 0001209191-23-043516 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,761 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043516 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,091 Underlying: Class A Common Stock · 137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043516 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 45 | $5.99 | $269.55 |
DisclosureSEC source: 0001209191-23-041212 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,685 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 99 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041212 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,092 Underlying: Class A Common Stock · 99 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 99 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041212 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 61 | $6.33 | $386.13 |
DisclosureSEC source: 0001209191-23-038752 · doc4.xml · nonDerivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,631 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,488 | $6.37 | $9,479.01 |
DisclosureSEC source: 0001209191-23-038752 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,692 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.23 to $6.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038752 · doc4.xml · derivative · entry 4 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,135 Underlying: Class A Common Stock · 3,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 3,410 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-038752 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 828 | $6.49 | $5,373.55 |
DisclosureSEC source: 0001209191-23-036826 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,770 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 1,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036826 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,515 Underlying: Class A Common Stock · 1,894 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,894 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-036826 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 26, 2023 Filed Apr 27, 2023 21:28 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 1,800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025899 · doc4.xml · derivative · entry 4 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Class A Common Stock · 1,800,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 26, 2023 Filed Apr 27, 2023 21:28 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,015 | $0.29 | $582.34 |
DisclosureSEC source: 0001209191-23-025899 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,205 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.281 to $0.3098, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:28 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025899 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,536 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:28 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-025899 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,731 | $0.34 | $586.98 |
DisclosureSEC source: 0001209191-23-023008 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,717 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple transactions at prices ranging from $0.3266 to $0.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 23:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023008 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,312 Underlying: Class A Common Stock · 3,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 23:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 3,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023008 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 23:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 32,787 | $0.36 | $11,796.76 |
DisclosureSEC source: 0001209191-23-018279 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,172 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3451 to $0.3608, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 23:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018279 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937,500 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 23:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018279 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,241 | $0.36 | $810.12 |
DisclosureSEC source: 0001209191-23-005236 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,204 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3578 to $0.3616, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005236 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005236 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:29 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,630 | $0.26 | $427.88 |
DisclosureSEC source: 0001209191-23-002123 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,942 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2582 to $0.2627, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 00:55 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001445 · doc4.xml · derivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,864 Underlying: Class A Common Stock · 3,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 00:55 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 3,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001445 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 09, 2022 Filed Dec 14, 2022 21:14 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061187 · doc4.xml · derivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2026-12-09 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 9, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 22:31 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,994 | $1.02 | $2,033.48 |
DisclosureSEC source: 0001209191-22-054742 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,296 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:31 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054742 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,542 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:31 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-054742 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 00:39 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,429 | $0.94 | $1,346.55 |
DisclosureSEC source: 0001209191-22-052571 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,787 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8605 to $1.1143, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:39 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052571 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,140 Underlying: Class A Common Stock · 3,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:39 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 3,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-052571 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 22:18 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 2,069 | $1.47 | $3,041.43 |
DisclosureSEC source: 0001209191-22-043283 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.47 to $1.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:18 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043283 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,045 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:18 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043283 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 05, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,021 | $1.32 | $1,346.39 |
DisclosureSEC source: 0001209191-23-026073 · doc4.xml · nonDerivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,761 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026073 · doc4.xml · derivative · entry 3 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,140 Underlying: Class A Common Stock · 3,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 3,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026073 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:50 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,430 | $2.18 | $3,117.69 |
DisclosureSEC source: 0001209191-22-026494 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,506 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.18 to $2.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 23:05 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025890 · doc4.xml · derivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,548 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 23:05 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-025890 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:17 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 52,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023519 · doc4.xml · derivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,416 Underlying: Class A Common Stock · 52,416 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:17 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 91,001 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023519 · doc4.xml · derivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,001 Underlying: Class A Common Stock · 91,001 shares Expires 2032-04-03 F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 28, 2022 Filed Feb 3, 2022 02:26 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,776 | $2.84 | $5,046.15 |
DisclosureSEC source: 0001209191-22-006610 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,433 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.84 to $2.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 01:28 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 4,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005287 · doc4.xml · derivative · entry 2 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,051 Underlying: Class A Common Stock · 4,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 01:28 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 4,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-005287 · doc4.xml · nonDerivative · entry 1 White Karen Ann · CIK 0001874118 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.